RWD/RWE top named opportunity area in PPD pharmaceutical industry survey

25 Oct 2022

Written by Linda Essex

Editorials Medical devices, pharmaceuticals and vaccines Real-world evidence

In the PPD 2022 state-of-industry survey, drug development companies worldwide named RWD/RWE the greatest area of opportunity. Many consider digital and decentralized clinical trials will improve patient recruitment, their top named challenge. PPD, the clinical research business of Thermo Fisher Scientific, surveyed 150+ leaders of drug development companies around the globe during 2022 to gather their insights on trends in pharmaceutical research and development. Greater use of RWD/RWE was the top named opportunity in their results, whilst patient recruitment to clinical trials was reported as the greatest current hurdle, with optimism that growth of digital and decentralized trials (DCT) will...